LIN Yiyi 1 , ZHAO Chen 2 , SHI Zhaofeng 1 , SONG Ke 1 , ZHAO Sai 1 , MA Bin 4 , LI Bo 3 , TIAN Guihua 1 , SHANG Hongcai 1 , NIE Bo 1
  • 1. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, P.R.China;
  • 2. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R.China;
  • 3. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, P.R.China;
  • 4. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P.R.China;
SHANG Hongcai, Email: shanghongcai@foxmail.com; NIE Bo, Email: nieboww_1977@163.com
Simiao Yong'an decoction; Atherosclerosis; Systematic review; Meta-analysis; Experiments on animals
10.7507/1672-2531.202012005
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To systematically review the interventional effects of Simiao Yong'an decoction on atherosclerosis animal models.Methods Database including CNKI, WanFang Data, VIP, PubMed, The Cochrane Library, and Web of Science were searched to collect animal experiments on atherosclerosis model intervention by Simiao Yong’an decoction from inception to October 2020. Two reviewers independently screened the literature, extracted data, and used the SYRCLE animal experiment bias risk assessment tool to evaluate risk bias of included studies, and then used RevMan 5.4.1 software for meta-analysis.Results A total of 14 animal experiments were included. The results of meta-analysis showed that compared with the blank model group, the Simiao Yong’an decoction group could reduce the aortic plaque area (SMD=−2.04, 95%CI −3.35 to −0.74), the ratio of aortic plaque to lumen area (SMD=−1.72, 95%CI −2.48 to −0.97), total cholesterol level (SMD=−0.97, 95 %CI −1.72 to −0.22), triglyceride level (SMD=−1.21, 95%CI −1.82 to −0.60), low-density lipoprotein cholesterol level (SMD=−1.82, 95%CI −3.12 to −1.53), tumor necrosis factor-α level (SMD=−3.36, 95%CI −4.21 to −2.52), monocyte chemotactic factor-1 level (SMD=−2.98, 95%CI −4.60 to −1.35) and C-reactive protein level (SMD=−0.60, 95%CI −1.08 to −0.11); however, in the high-density lipoprotein cholesterol level (SMD=0.66, 95%CI −0.10 to 1.42) and the level of interleukin 1 (SMD=−1.41, 95%CI −4.11 to 1.30), the differences were not statistically significant.Conclusions The existing evidence shows that the intervention of Simiao Yong’an decoction in the atherosclerosis model can reduce the aortic plaque area and the ratio of the aortic plaque to the lumen area, reduce total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, and reduce tumor necrosis factor-α, monocyte chemotactic factor-1, and C-reactive protein levels. Due to limited quality of included studies, more high quality studies are required to verify the above conclusions.

Citation： LIN Yiyi, ZHAO Chen, SHI Zhaofeng, SONG Ke, ZHAO Sai, MA Bin, LI Bo, TIAN Guihua, SHANG Hongcai, NIE Bo. Simiao Yong'an decoction for the treatment of atherosclerosis in animal experiment: a systematic review. Chinese Journal of Evidence-Based Medicine, 2021, 21(5): 559-565. doi: 10.7507/1672-2531.202012005 Copy

  • Previous Article

    Effect of implementing of the medicines zero mark-up policy in Chinese public hospitals: a systematic review

  • Next Article

    Diagnostic value of capsule endoscopy and enteroscopy in small bowel diseases: a meta-analysis